Ketamine for Major Depressive Disorder
Phase 1
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: SHX-001 Active low doseDrug: PlaceboDrug: SHX-001 Active High dose
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Shenox Pharmaceuticals, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT03721900
- Locations
- 🇺🇸
Clinical Research Site, Dayton, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath